Lexaria Bioscience Corp. immediately exercised Existing Warrants covering 453,969 common shares at a reduced $12.92 per-share price, generating approximately $5.9 million in gross proceeds. The transaction also gives eligible holders new Series A and Series B warrants at $12.67 per share, while proceeds are earmarked for Working Capital and general corporate purposes.

Key Highlights

  • Series A Warrants and Series B Warrants carry a $12.67 per-share exercise price and different terms.
  • The Placement agent received warrants covering 15,889 common shares at $16.15 per share and a 7% fee.
  • Beneficial ownership limits cap exercise at 4.99%, with an increase to 9.99% available after prior notice.

The transaction generated approximately $5.9 million in gross proceeds before placement agent fees and estimated offering expenses. The company said it expects to use the net proceeds for working capital and general corporate purposes.

Eligible holders will receive Series A Warrants covering up to an aggregate of 453,969 common shares, with an exercise price of $12.67 per share. The Series A Warrants are immediately exercisable and run for five years from the effective date. Series B Warrants will also cover up to an aggregate of 453,969 common shares and carry a $12.67 per-share exercise price. Those warrants are immediately exercisable with an eighteen-month term from the effective date. The new warrants are unregistered. Lexaria Bioscience (NASDAQ: LEXX) agreed to provide for the resale registration of the common shares issuable when holders exercise them.

Ownership Limits Govern Exercise

The inducement arrangements apply to certain holders of Existing Warrants. Those warrants were originally issued on February 16, 2024, at an exercise price of $32.78 per share; October 16, 2024, at $45.90 per share; September 29, 2025, at $20.55 per share; and December 16, 2025, at $17.85 per share. A holder may not receive enough shares through exercise to exceed a beneficial ownership limit of 4.99% of outstanding common stock after the transaction. The limit may be increased to 9.99% after at least 61 days' prior notice to Lexaria Bioscience. Shares that cannot be issued immediately because of the ownership ceiling will remain in abeyance until the holder provides notice that issuing them would comply with the limitation.

Placement Terms Set September Closing

H.C. Wainwright & Co. LLC acted as exclusive placement agent for the transactions. The company also issued the placement agent or its designees warrants covering up to 15,889 common shares at an exercise price of $16.15 per share. The related transactions were expected to close on September 9, 2026, subject to customary closing conditions. Lexaria Bioscience identified working capital and general corporate purposes as the uses for the net proceeds.